Autoimmune hepatitis. Part A: pathogenesis

References

• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology36, 479–497 (2002).
   PubMed Web of Science ®Google Scholar
• Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med.354, 54–66 (2006).
   PubMed Web of Science ®Google Scholar
• Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology43(Suppl.1), S132-S144 (2006).
   PubMedGoogle Scholar
• Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol.31, 929–938 (1999).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am. J. Gastroenterol.96, 1224–1231 (2001).
   PubMed Web of Science ®Google Scholar
• Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin. Liver Dis.6, 727–737 (2002).
   PubMedGoogle Scholar
• Rose NR. Fundamental concepts of autoimmunity and autoimmune disease. In: Autoimmune Liver Diseases, (2nd Edition). Krawitt EL, Wiesner RH, Nishioka M (Eds). Elsevier Science Publishers, New York, USA, 1–20 (1998).
   Google Scholar
• Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplantation8, 505–513 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig. Dis. Sci.47, 2139–2150 (2002).
   PubMed Web of Science ®Google Scholar
• Brown JH, Jardetsky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature332, 845–850 (1988).
   PubMed Web of Science ®Google Scholar
• Doherty DG, Penzotti JE, Koelle DM et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J. Immunol.161, 3527–3535 (1998).
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology13, 701–706 (1991).
   PubMed Web of Science ®Google Scholar
• Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology19, 609–615 (1994).
   PubMed Web of Science ®Google Scholar
• Strettell MDJ, Donaldson PT, Thomson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology112, 2028–2035 (1997).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology25, 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am. J. Gastroenterol.97, 2051–2057 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev.174, 250–259 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshizawa K, Ota M, Katsuyama Y et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J. Hepatol.42, 578–584 (2005).
   PubMed Web of Science ®Google Scholar
• Vazquez-Garcia MN, Alaez C, Olivo A et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J. Hepatol.28, 985–990 (1998).
   PubMed Web of Science ®Google Scholar
• Qiu D-K, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J. Gastroenterol. Hepatol.218, 63–67 (2003).
   Google Scholar
• Penzotti JE, Doherty DG, Lybrand TP, Nepom GT. A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis. J. Autoimmun.9, 287–293 (1996).
   PubMed Web of Science ®Google Scholar
• Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity7, 473–481 (1997).
   PubMed Web of Science ®Google Scholar
• Pando M, Larriba J, Fernandez GC et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology30, 1374–1380 (1999).
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Bittencourt PL, Mougin B et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum. Immunol.62, 165–169 (2001).
   PubMed Web of Science ®Google Scholar
• Fainboim L, Velasco VCC, Marcos CY et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology33, 1512–1517 (2001).
   PubMedGoogle Scholar
• Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol.30, 394–401 (1999).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem.40, 127–164 (2005).
   PubMed Web of Science ®Google Scholar
• Homberg J-C, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ‘autoimmune’ hepatitis. Hepatology7, 1333–1339 (1987).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am. J. Gastroenterol.90, 1206–1211 (1995).
   PubMed Web of Science ®Google Scholar
• Bittencourt PL, Goldberg AC, Cancado ELR et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am. J. Gastroenterol.94, 1906–1913 (1999).
   PubMed Web of Science ®Google Scholar
• Ma Y, Bogdanos DP, Hussain MJ et al. Polyclonal T-cell responses to cytokine P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology130, 868–882 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am. J. Gastroenterol.92, 2197–2200 (1997).
   PubMed Web of Science ®Google Scholar
• Jurado A, Cardaba B, Jara P et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. J. Hepatol.26, 983–991 (1997).
   PubMed Web of Science ®Google Scholar
• Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J. Hepatol.45, 844–850 (2006).
   PubMed Web of Science ®Google Scholar
• Muratori P, Czaja AJ, Muratori L et al. Evidence of a genetic basis for the different geographical occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig. Dis. Sci.52, 179–184 (2007).
   PubMedGoogle Scholar
• Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology103, 1290–1295 (1992).
   PubMed Web of Science ®Google Scholar
• Reddy KR, Krawitt EL, Homberg JC et al. Absence of anti-LKM1 antibody in hepatitis C viral infection in the United States of America. J. Viral Hepat.2, 175–179 (1995).
   PubMedGoogle Scholar
• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am. J. Gastroenterol.97, 413–419 (2002).
   PubMed Web of Science ®Google Scholar
• Ma Y,Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology35, 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Montano-Loza A, Carpenter HA, Czaja AJ. Clinical significance of of HLA DRB1*03-DRB1*04 in type 1 autoimmune hepatitis. Liver Int.26, 1201–1208 (2006).
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int.26, 552–558 (2006).
   PubMedGoogle Scholar
• Kurokohchi K, Masaki T, Himoto T et al. Usefulness of liver infiltrating CD86-positive mononuclear cells for diagnosis of autoimmune hepatitis. World J. Gastroenterol.12, 25230–25239 (2006).
   Google Scholar
• Kurokohchi K, Arima K, Masaki T et al. Analysis of CD28 and bcl-2 expression on peripheral blood and liver-infiltrating mononuclear cells in patients with autoimmune hepatitis. J. Clin. Immunol.26, 323–330 (2006).
   PubMedGoogle Scholar
• Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology31, 49–53, (2000).
   PubMed Web of Science ®Google Scholar
• Agarwal K, Jones DE, Daly AK et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol.32, 538–541 (2000).
   PubMed Web of Science ®Google Scholar
• Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver21, 272–279 (2001).
   PubMedGoogle Scholar
• Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and other conditions. Autoimmun. Rev.2, 36–42 (2003).
   PubMed Web of Science ®Google Scholar
• Ogawa S, Sakaguchi K, Takaki A et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J. Gastroenterol. Hepatol.15, 69–75 (2000).
   PubMed Web of Science ®Google Scholar
• Ichiki Y, Aoki CA, Bowlus CL et al. T cell immunity in autoimmune hepatitis. Autoimmun. Rev.4, 315–321 (2005).
   PubMed Web of Science ®Google Scholar
• Hirade A, Imazeki F, Yokosuka O et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am. J. Gastroenterol.100, 1322–1329 (2005).
   PubMedGoogle Scholar
• Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens69, 227–235 (2007).
   PubMedGoogle Scholar
• Lohr HF, Schaak JF, Gerken G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde K-H. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver14, 161–166 (1994).
   PubMedGoogle Scholar
• Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig. Dis. Sci.45, 1028–1035 (2000).
   PubMed Web of Science ®Google Scholar
• Fan L-Y, Tu X-Q, Zhu Y et al. Genetic association of cytokine polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J. Gastroenterol.11, 2768–2772 (2005).
   PubMedGoogle Scholar
• Cookson S, Constantini PK, Clare M et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology30, 851–856 (1999).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology117, 645–652 (1999).
   PubMed Web of Science ®Google Scholar
• Lin JT, Kitzmiller TJ, Cates JMM, Gorham JD. MHC-independent genetic regulation of liver damage in a mouse model of autoimmune hepatocellular injury. Lab. Invest.85, 550–561 (2005).
   PubMedGoogle Scholar
• Vogel A, Strassburg CP, Manns MP: Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology35, 126–131 (2002).
   PubMed Web of Science ®Google Scholar
• Esteghamat F, Noorinayer B, Sanati MH et al. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol. Res.32, 154–157 (2005).
   PubMedGoogle Scholar
• Lankisch TO, Strassburg CP, Debray D, Manns MP, Jacquemin E. Detection of autoimmune regulator gene mutations in children with type 2 autoimmune hepatitis and extrahepatic immune-mediated diseases. J. Pediatr.146, 839–842 (2005).
   PubMedGoogle Scholar
• Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun.25, 133–140 (2005).
   PubMedGoogle Scholar
• Lapierre P, Beland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J. Autoimmun.26, 82–89 (2006).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Ma Y, Mitry RR et al. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun.25, 63–71 (2005).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Hussain MJ, Mitry RR et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J. Immunol.176, 4484–4491 (2006).
   PubMed Web of Science ®Google Scholar
• Lan RY, Cheng C, Lian ZX et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology43, 729–737 (2006).
   PubMed Web of Science ®Google Scholar
• Zachou Z, Rigopoulou EI, Tsikrikoni A et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J. Autoimmun.25, 283–288 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do ’NK-reg cells’ exist? Cell Mol. Immunol.3, 241–254 (2006).
   PubMed Web of Science ®Google Scholar
• Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem.6, 1249–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. U.S.A.97, 5498–5503 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Oikawa T, Amano K et al. Intrahepatic NKT cell and soluble CD1d have a significant role in the immuno-pathogenesis of AIH but not in PBC (abstract). Hepatology44(Suppl. 1), 227A–228A (2006).
   Google Scholar
• Martins EB, Graham AK, Chapman RW, Fleming KA. Elevation of γδ T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology23, 988–993 (1996).
   PubMedGoogle Scholar
• Bluestone JA, Cron RQ, Cotterman M, Houlden BA, Matis LA. Structure and specificity of T cell receptor γ/δ on major histocompatibility complex antigen-specific CD3+, CD4-, CD8- T lymphocytes. J. Exp. Med.168, 1899–1916 (1988).
   PubMedGoogle Scholar
• Strominger J. The γ/δ Tcell receptor and class Ib MHC-related proteins: enigmatic molecules of immune recognition. Cell57, 895–989 (1989).
   PubMedGoogle Scholar
• Wen L, Ma Y, Bogdanos DP et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr. Mol. Med.1, 379–389 (2001).
   PubMedGoogle Scholar
• Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol. Rev.195, 58–71 (2003).
   PubMed Web of Science ®Google Scholar
• Heydtmann M, Lalor PF, Eksteen JA. Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed liver. J. Immunol.174, 1055–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Ajuebor MN, Aspinall AI, Zhou F et al. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J. Immunol.174, 8027–8037 (2005).
   PubMed Web of Science ®Google Scholar
• Moreno C, Gustot T, Nicaise C et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology42, 854–862 (2005).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver21, 225–232 (2001).
   PubMedGoogle Scholar
• Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N. Engl. J. Med.341, 2068–2074 (1999).
   PubMed Web of Science ®Google Scholar
• Kammer AR, van der Burg SH, Grabscheid B et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med.190, 169–176 (1999).
   PubMed Web of Science ®Google Scholar
• Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology39, 1066–1074 (2004).
   PubMed Web of Science ®Google Scholar
• Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest.88, 1370–1378 (1991).
   PubMed Web of Science ®Google Scholar
• Ma Y, Thomas MG, Okamoto M et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J. Immunol.169, 277–285 (2002).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Choudhuri K, Ma Y et al. Cytochrome P4502D6193–212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol.170, 1481–1489 (2003).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Choudhuri K, Ma Y et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C infection. Clin. Exp. Immunol.133, 404–413 (2003).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Lenzi M, Okamoto M et al. Multiple viral/self immunological cross reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients associated with the possession of HLA B51. Int. J. Immunopathol. Pharmacol.17, 83–92 (2004).
   PubMed Web of Science ®Google Scholar
• Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology26, 1054–1066 (1997).
   PubMed Web of Science ®Google Scholar
• Aguilera I, Wichmann I, Sousa JM, Bernardos A et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin. Exp. Immunol.126, 535–539 (2001).
   PubMedGoogle Scholar
• Muratori L, Sztul E, Muratori P et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology34, 494–501 (2001).
   PubMed Web of Science ®Google Scholar
• Costa M, Rodriques-Sanchez JL, Czaja AJ et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNA(Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin. Exp. Immunol.121, 364–374 (2000).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig. Dis. Sci.43, 2149–2155 (1998).
   PubMed Web of Science ®Google Scholar
• McFarlane IG, Heneghan MA. Autoimmunity and the female liver. Hepatol. Res.28, 171–176 (2004).
   PubMed Web of Science ®Google Scholar
• Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science283, 1277–1278 (1999).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Reid F et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology25, 541–547 (1997).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology43, 532–538 (2006).
   PubMed Web of Science ®Google Scholar
• Lambert NC, Evans PC, Hashizumi TL et al. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications for autoimmunity. J. Immunol.164, 5545–5548 (2000).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology105, 1502–1507 (1993).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Santrach PJ, Moore SB. Shared genetic risk factors in autoimmune liver disease. Dig. Dis. Sci.46, 140–147 (2001).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D. Shared autoimmunity: a concept for which the time has come. Autoimmunity38, 201–203 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopath.84, 223–243 (1997).
   PubMedGoogle Scholar